Replies to post #202090 on Biotech Values

[DewDiligence]

MATN* phase-2 in ovarian cancer pasued due to AEs:

https://finance.yahoo.com/news/mateon-therapeutics-provides-clinical-trial-113000564.html

The PAZOFOS study is a phase 1b/2 investigator-sponsored study being conducted in the U.K., evaluating the combination of CA4P and the TKI-inhibitor pazopanib for patients with advanced recurrent ovarian cancer. To date, the study has enrolled and treated 20 patients with CA4P and pazopanib in the phase 1b and phase 2 portions of the trial.

The study sponsor, The Christie NHS Trust, has temporarily suspended enrollment in the trial in order to collect and review additional information on two recent serious adverse events – one patient in the study experienced hypertension and myocardial ischemia, and a second patient experienced chest pain. In both cases, the events were of short duration and the clinical symptoms resolved.

This nugget was buried deep within a “clinical update” PR.

*f/k/a/ OXGN.